Treatment Sequencing Decisions in ALK+ NSCLC

Opinion
Video

This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.

Video content above is prompted by the following:

  • If this patient were to experience disease progression on lorlatinib, what would be your next therapeutic approach and why?
    • What considerations would guide your decision-making process?
  • If this patient had started on a different ALK inhibitor, when/why might you consider a switch to lorlatinib?
Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content
Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

Surgery Trends Towards Improved Outcomes Vs SABR in Elderly NSCLC Group

Russ Conroy
February 27th 2025
Article

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC

Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC

Tim Cortese
February 19th 2025
Article

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

FDA Grants Fast Track Designation to IBI363 in Pretreated Squamous NSCLC

FDA Grants Fast Track Designation to IBI363 in Pretreated Squamous NSCLC

Tim Cortese
February 17th 2025
Article

IBI363 demonstrated encouraging efficacy and a manageable safety profile in patients with squamous NSCLC based on results from a phase 1 trial.

Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective

Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective

ONCOLOGY Staff
February 8th 2025
Article

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.